Jonathan Jay  Mazelsky net worth and biography

Jonathan Mazelsky Biography and Net Worth

Mr. Mazelsky has served as President and Chief Executive Officer of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Interim President and Chief Executive Officer from June 2019 to October 2019, and he was an Executive Vice President responsible for our North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including our IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor’s degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.

What is Jonathan Jay Mazelsky's net worth?

The estimated net worth of Jonathan Jay Mazelsky is at least $37.75 million as of February 7th, 2024. Mr. Mazelsky owns 79,247 shares of IDEXX Laboratories stock worth more than $37,749,308 as of April 21st. This net worth estimate does not reflect any other investments that Mr. Mazelsky may own. Additionally, Mr. Mazelsky receives an annual salary of $2,040,000.00 as CEO at IDEXX Laboratories. Learn More about Jonathan Jay Mazelsky's net worth.

How old is Jonathan Jay Mazelsky?

Mr. Mazelsky is currently 63 years old. There are 5 older executives and no younger executives at IDEXX Laboratories. Learn More on Jonathan Jay Mazelsky's age.

What is Jonathan Jay Mazelsky's salary?

As the CEO of IDEXX Laboratories, Inc., Mr. Mazelsky earns $2,040,000.00 per year. Learn More on Jonathan Jay Mazelsky's salary.

How do I contact Jonathan Jay Mazelsky?

The corporate mailing address for Mr. Mazelsky and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on Jonathan Jay Mazelsky's contact information.

Has Jonathan Jay Mazelsky been buying or selling shares of IDEXX Laboratories?

Jonathan Jay Mazelsky has not been actively trading shares of IDEXX Laboratories in the last ninety days. Most recently, Jonathan Jay Mazelsky sold 12,000 shares of the business's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a transaction totalling $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares of the company's stock, valued at $45,377,624.67. Learn More on Jonathan Jay Mazelsky's trading history.

Who are IDEXX Laboratories' active insiders?

IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), George Fennell (SVP), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.

Are insiders buying or selling shares of IDEXX Laboratories?

During the last year, insiders at the sold shares 11 times. They sold a total of 127,835 shares worth more than $67,745,986.38. The most recent insider tranaction occured on February, 8th when SVP George Fennell sold 8,198 shares worth more than $4,704,586.26. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.

Information on this page was last updated on 2/8/2024.

Jonathan Jay Mazelsky Insider Trading History at IDEXX Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2024Sell12,000$572.61$6,871,320.0079,247View SEC Filing Icon  
12/4/2023Sell7,128$513.05$3,657,020.4079,233View SEC Filing Icon  
8/31/2023Sell13,424$512.01$6,873,222.2472,925View SEC Filing Icon  
11/14/2022Sell10,500$434.47$4,561,935.0070,805View SEC Filing Icon  
11/7/2022Sell13,230$382.49$5,060,342.7062,307View SEC Filing Icon  
2/17/2021Sell13,868$537.21$7,450,028.2868,090View SEC Filing Icon  
11/5/2020Sell5,206$469.31$2,443,227.86View SEC Filing Icon  
See Full Table

Jonathan Jay Mazelsky Buying and Selling Activity at IDEXX Laboratories

This chart shows Jonathan Jay Mazelsky's buying and selling at IDEXX Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IDEXX Laboratories Company Overview

IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $476.35
Low: $471.42
High: $482.21

50 Day Range

MA: $538.02
Low: $476.35
High: $576.87

2 Week Range

Now: $476.35
Low: $372.50
High: $583.39

Volume

568,646 shs

Average Volume

376,960 shs

Market Capitalization

$39.56 billion

P/E Ratio

47.30

Dividend Yield

N/A

Beta

1.26